Engineering bispecific antibodies for non-hormonal contraception
用于非激素避孕的双特异性抗体工程
基本信息
- 批准号:10428467
- 负责人:
- 金额:$ 52万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-04-01 至 2024-03-31
- 项目状态:已结题
- 来源:
- 关键词:AffinityAgglutinationAnatomyAnimal ModelAntibodiesAntibody FormationAntigen TargetingAntigensBindingBiological AssayBispecific AntibodiesBostonCellsCervix MucusClinical TrialsComputer AssistedContraceptive AgentsContraceptive VaccinesContraceptive methodsDepositionDevelopmentDoseEmbryoEngineeringEnzyme-Linked Immunosorbent AssayFab domainFederal GovernmentFertilityFormulationHistologyHistopathologyHumanImmuneImmunoglobulin GImmunoglobulin MImmunologic ContraceptionIndividualInfertilityInflammationKineticsLeadLibrariesLinkMacacaMale Genital OrgansMeasuresMethodsModelingMonoclonal AntibodiesMucinsMucous body substanceOocytesOryctolagus cuniculusParentsPassive ImmunizationPenetrationPhase I Clinical TrialsPilot ProjectsPolymersProductionProtease InhibitorResearchSafetySamplingSeminal fluidSheepSpecificitySperm AgglutinationSperm MotilitySpermatozoa antibodyState GovernmentSurfaceSurface AntigensSwimmingTechnologyTestingTight JunctionsTimeTissuesUniversitiesVaccinesVaginaVaginal RingVaginal delivery procedureWomanYeastsZona Pellucidaantibody engineeringbasebioprocesscell motilitycervicovaginalcontraceptive efficacycontraceptive targetcostcrosslinkcytokinegel electrophoresisgenital secretionimprovedin vivonext generationnovelpathogenpre-clinical assessmentpreventreproductive tractreversible contraceptivesperm analysissperm cellunintended pregnancyvaccine responsezygote
项目摘要
Summary
Sperm must swim through mucus before ascending to the upper tract and fertilizing the egg. In addition, sperm
must be hyperactivated to penetrate the zona pellucida of the oocyte. Polymeric antibodies (Ab) such as IgM
that bind sperm surface antigens can agglutinate sperm into clusters too large to penetrate through the pores
of mucus. In addition, IgG can also be engineered to crosslink individual sperm to mucins, as well as inhibit
hyperactivation, consequently preventing sperm from reaching and fertilizing the egg. Topical passive
immunization based on vaginal delivery of anti-sperm Ab (ASA) was validated in animal models in the
1980s-1990s, and directly overcomes the variable intensity and uncertain reversibility of contraceptive
vaccines. However, this strategy was not practical due to the high costs of mAb production and challenges
with IgM formulation. Given the remarkable advances in bioprocessing that have greatly reduced the costs
of mAb manufacturing, and the possibility of sustained delivery of antibodies in the vagina via intravaginal
rings, we believe the time is now ripe to develop novel, ultra-potent ASA for non-hormonal contraception
based on topical passive immunization of the vagina against human sperm. In pilot studies, we have shown
that we can greatly increase the sperm-agglutination potency of ASA by >15-50-fold by engineering
multivalent, IgG-based construct comprised of six to ten Fab domains (i.e. 4 to 8 additional Fabs linked to the
parent IgG molecule). These novel constructs possess comparable stability to IgG in accelerated thermal
stability studies, and also similar production and purification yield as IgG. One of the constructs represent the
lead molecule under development in the Boston University Contraceptive Research Center, with two Phase I
clinical trials slated to begin in 2020. In this project, we seek to further improve the potencies by employing
cutting edge bispecific Ab engineering technology and affinity maturation via yeast and mamallian cell display
to engineer a library of ultra-potent bispecific multivalent ASA constructs. We will target both CD52g, a well
characterized and validated antigen target present on human sperm only, and EPPIN, a well established
contraceptive target that functions by inhibiting sperm hyperactivation. In Aim 1, we will utilize yeast display to
improve the affinity of Fab against CD52g and EPPIN, engineer a library of multivalent bispecific constructs
that bind both targets, and rigorously characterize these molecules. In Aim 2, we will perform a panel of
studies to assess their potential contraceptive efficacy, including sperm agglutination, trapping individual sperm
in mucus, and inhibition of sperm hyperactivation. To determine which construct will most effectively reduce
progressive sperm motility in human vagina, we will perform in vivo dose finding studies in Aim 3 with the two
most potent constructs from Aims 1 and 2 in a post-coital fertility test adapted to the sheep vagina. Successful
completion of these studies will likely allow us to advance a novel ASA candidate with substantially greater
contraceptive potency than the current ASA molecules under development for non-hormonal contraception.
总结
精子在上升到上生殖道并与卵子结合之前,必须游过粘液。此外,精子
必须被超活化才能穿透卵母细胞的透明质膜。聚合抗体(Ab),如IgM
结合精子表面抗原的蛋白质可以使精子凝集成大到无法穿过小孔的团
粘液。此外,IgG还可以被工程化以将个体精子交联到粘蛋白,以及抑制精子的生长。
过度激活,从而阻止精子到达卵子并使卵子受精。话题被动语态
基于抗精子抗体(阿萨)阴道给药的免疫接种在动物模型中得到了验证,
1980 - 1990年代,并直接克服了避孕的可变强度和不确定的可逆性
疫苗。然而,由于mAb生产的高成本和挑战,这种策略并不实用。
IgM的配方。鉴于生物加工技术的显著进步大大降低了成本
单克隆抗体的生产,以及通过阴道内持续递送抗体的可能性
戒指,我们相信现在开发用于非激素避孕的新型、超强效阿萨的时机已经成熟
基于阴道对人类精子的局部被动免疫。在试点研究中,我们已经表明,
我们可以通过工程改造将阿萨的精子凝集效力大大提高>15-50倍
多价的基于IgG的构建体包含6至10个Fab结构域(即4至8个连接至Fab结构域的另外的Fab)。
亲本IgG分子)。这些新的构建体在加速热老化中具有与IgG相当的稳定性。
稳定性研究,以及与IgG相似的生产和纯化产率。其中一个构造表示
波士顿大学避孕研究中心正在开发一种领先的分子,
临床试验定于2020年开始。在这个项目中,我们试图通过使用
尖端的双特异性抗体工程技术和通过酵母和哺乳动物细胞展示的亲和力成熟
以工程改造超有效双特异性多价阿萨构建体的文库。我们将靶向CD 52 g,
已表征和验证的抗原靶点仅存在于人精子上,而EPPIN是一种成熟的
通过抑制精子过度活化发挥作用的避孕靶点。在目标1中,我们将利用酵母展示,
提高Fab对CD 52 g和EPPIN的亲和力,工程化多价双特异性构建体文库
结合这两个目标,并严格地描述这些分子。在目标2中,我们将执行一组
评估其潜在避孕效果的研究,包括精子凝集、捕获单个精子
和抑制精子过度活化。为了确定哪种结构将最有效地减少
在人类阴道中的精子运动性,我们将在目标3中使用两种药物进行体内剂量探索研究
在适应绵羊阴道的性交后生育力试验中,来自目的1和2的最有效的构建体。成功
这些研究的完成将可能使我们能够推进一种新的阿萨候选药物,
避孕效力比目前正在开发的非激素避孕的阿萨分子。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Samuel Lai其他文献
Samuel Lai的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Samuel Lai', 18)}}的其他基金
Engineering Siglec15/TGF-beta targeted bispecific antibodies that modulate the tumor microenvironment and enhances T-cell immunotherapy against pancreatic cancer
工程化 Siglec15/TGF-β 靶向双特异性抗体可调节肿瘤微环境并增强针对胰腺癌的 T 细胞免疫治疗
- 批准号:
10651442 - 财政年份:2023
- 资助金额:
$ 52万 - 项目类别:
Engineered “muco-trapping” antibodies for inhaled therapy of parainfluenza and human metapneumovirus infections
用于副流感和人类偏肺病毒感染吸入治疗的工程化“粘膜捕获”抗体
- 批准号:
10707403 - 财政年份:2022
- 资助金额:
$ 52万 - 项目类别:
Engineered “muco-trapping” antibodies for inhaled therapy of parainfluenza and human metapneumovirus infections
用于副流感和人类偏肺病毒感染吸入治疗的工程化“粘膜捕获”抗体
- 批准号:
10587723 - 财政年份:2022
- 资助金额:
$ 52万 - 项目类别:
Engineering bispecific antibodies for non-hormonal contraception
用于非激素避孕的双特异性抗体工程
- 批准号:
10618849 - 财政年份:2020
- 资助金额:
$ 52万 - 项目类别:
Overcoming anti-PEG immunity to restore prolonged circulation and efficacy of PEGylated therapeutics
克服抗 PEG 免疫,恢复 PEG 化治疗的延长循环和功效
- 批准号:
10181024 - 财政年份:2018
- 资助金额:
$ 52万 - 项目类别:
Artificial neural networks for high performance, fully automated particle tracking analysis even at low signal-to-noise regimes
人工神经网络即使在低信噪比条件下也能实现高性能、全自动粒子跟踪分析
- 批准号:
9347679 - 财政年份:2017
- 资助金额:
$ 52万 - 项目类别:
Prevalence and characteristics of anti-PEG antibodies in humans
人类抗 PEG 抗体的流行率和特征
- 批准号:
8622684 - 财政年份:2014
- 资助金额:
$ 52万 - 项目类别:
Optimizing Plantibodies for Trapping HIV and HSV in Cervicovaginal Mucus
优化 Plantibodies 以捕获宫颈阴道粘液中的 HIV 和 HSV
- 批准号:
8803845 - 财政年份:2014
- 资助金额:
$ 52万 - 项目类别:
Optimizing Plantibodies for Trapping HIV and HSV in Cervicovaginal Mucus
优化 Plantibodies 以捕获宫颈阴道粘液中的 HIV 和 HSV
- 批准号:
8515320 - 财政年份:2013
- 资助金额:
$ 52万 - 项目类别:
相似海外基金
Point-of-Care Device for Microfluidic Quantification of Agglutination
用于凝集微流体定量的护理点设备
- 批准号:
563571-2021 - 财政年份:2021
- 资助金额:
$ 52万 - 项目类别:
University Undergraduate Student Research Awards
Microfluidic Agglutination Quantification Through Deep Learning
通过深度学习进行微流控凝集定量
- 批准号:
553149-2020 - 财政年份:2020
- 资助金额:
$ 52万 - 项目类别:
University Undergraduate Student Research Awards
SBIR Phase II: Developing a Platform for Multiplexed Drug Profiling Using Yeast Synthetic Agglutination
SBIR 第二阶段:开发利用酵母合成凝集进行多重药物分析的平台
- 批准号:
1950992 - 财政年份:2020
- 资助金额:
$ 52万 - 项目类别:
Standard Grant
A portable agglutination test with automated serial dilution for COVID-19 infection and immunity
具有自动连续稀释功能的便携式凝集测试,用于检测 COVID-19 感染和免疫
- 批准号:
554378-2020 - 财政年份:2020
- 资助金额:
$ 52万 - 项目类别:
Alliance Grants
SBIR Phase I: Developing a Platform for Multiplexed Drug Profiling Using Yeast Synthetic Agglutination
SBIR 第一阶段:开发利用酵母合成凝集进行多重药物分析的平台
- 批准号:
1819398 - 财政年份:2018
- 资助金额:
$ 52万 - 项目类别:
Standard Grant
SBIR Phase II: Development of an ultrasensitive, high-throughput autoantibody discovery platform using agglutination-PCR
SBIR 第二阶段:使用凝集 PCR 开发超灵敏、高通量自身抗体发现平台
- 批准号:
1758698 - 财政年份:2018
- 资助金额:
$ 52万 - 项目类别:
Standard Grant
SBIR Phase I: Development of an ultrasensitive, high-throughput autoantibody discovery platform using agglutination-PCR
SBIR 第一阶段:使用凝集 PCR 开发超灵敏、高通量自身抗体发现平台
- 批准号:
1622257 - 财政年份:2016
- 资助金额:
$ 52万 - 项目类别:
Standard Grant
Antibody-Detection-by-Agglutination-PCR (ADAP): An Ultra-Sensitive, High-Throughput, Multiplexable Tool for T1D Diagnosis and Monitoring
凝集 PCR 抗体检测 (ADAP):一种用于 T1D 诊断和监测的超灵敏、高通量、可多重工具
- 批准号:
9185244 - 财政年份:2016
- 资助金额:
$ 52万 - 项目类别:
Developing a Z-domain based latex agglutination assay for C. difficile toxins
开发基于 Z 结构域的艰难梭菌毒素乳胶凝集测定
- 批准号:
8831924 - 财政年份:2015
- 资助金额:
$ 52万 - 项目类别:
Molecular basis and intervention of Staphylococcus aureus agglutination
金黄色葡萄球菌凝集的分子基础及干预
- 批准号:
8817809 - 财政年份:2014
- 资助金额:
$ 52万 - 项目类别: